1. Home
  2. NICE Guidance
  3. In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

  • Project information
  • Project documents

Documents

A list of downloadable documents created during development.

Draft scope documents

  • Draft scope (post-referral) PDF 138.65 KB 29 February 2016  
  • Provisional matrix (post-referral) PDF 95.28 KB 29 February 2016